Literature DB >> 23965743

Skeletal muscle biopsy analysis in reducing body myopathy and other FHL1-related disorders.

Edoardo Malfatti1, Montse Olivé, Ana Lía Taratuto, Pascale Richard, Guy Brochier, Marc Bitoun, Lucie Gueneau, Pascal Laforêt, Tanya Stojkovic, Thierry Maisonobe, Soledad Monges, Fabiana Lubieniecki, Gabriel Vasquez, Nathalie Streichenberger, Emmanuelle Lacène, Maria Saccoliti, Bernard Prudhon, Marilena Alexianu, Dominique Figarella-Branger, Joachim Schessl, Carsten Bonnemann, Bruno Eymard, Michel Fardeau, Gisèle Bonne, Norma Beatriz Romero.   

Abstract

FHL1 mutations have been associated with various disorders that include reducing body myopathy (RBM), Emery-Dreifuss-like muscular dystrophy, isolated hypertrophic cardiomyopathy, and some overlapping conditions. We report a detailed histochemical, immunohistochemical, electron microscopic, and immunoelectron microscopic analyses of muscle biopsies from 18 patients carrying mutations in FHL1: 14 RBM patients (Group 1), 3 Emery-Dreifuss muscular dystrophy patients (Group 2), and 1 patient with hypertrophic cardiomyopathy and muscular hypertrophy (Group 2). Group 1 muscle biopsies consistently showed RBs associated with cytoplasmic bodies. The RBs showed prominent FHL1 immunoreactivity whereas desmin, αB-crystallin, and myotilin immunoreactivity surrounded RBs. By electron microscopy, RBs were composed of electron-dense tubulofilamentous material that seemed to spread progressively between the myofibrils and around myonuclei. By immunoelectron microscopy, FHL1 protein was found exclusively inside RBs. Group 2 biopsies showed mild dystrophic abnormalities without RBs; only minor nonspecific myofibrillar abnormalities were observed under electron microscopy. Molecular analysis revealed missense mutations in the second FHL1 LIM domain in Group 1 patients and ins/del or missense mutations within the fourth FHL1 LIM domain in Group 2 patients. Our findings expand the morphologic features of RBM, clearly demonstrate the localization of FHL1 in RBs, and further illustrate major morphologic differences among different FHL1-related myopathies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23965743      PMCID: PMC5210222          DOI: 10.1097/NEN.0b013e3182a23506

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  19 in total

Review 1.  The LIM domain: from the cytoskeleton to the nucleus.

Authors:  Julie L Kadrmas; Mary C Beckerle
Journal:  Nat Rev Mol Cell Biol       Date:  2004-11       Impact factor: 94.444

2.  Unfolded protein response and aggresome formation in hereditary reducing-body myopathy.

Authors:  Teerin Liewluck; Yukiko K Hayashi; Maki Ohsawa; Rumi Kurokawa; Masako Fujita; Satoru Noguchi; Ikuya Nonaka; Ichizo Nishino
Journal:  Muscle Nerve       Date:  2007-03       Impact factor: 3.217

3.  KyoT3, an isoform of murine FHL1, associates with the transcription factor RBP-J and represses the RBP-J-mediated transactivation.

Authors:  Liang Liang; Hong-Wei Zhang; Jie Liang; Xiao-Li Niu; Su-Zhen Zhang; Lei Feng; Ying-Min Liang; Hua Han
Journal:  Biochim Biophys Acta       Date:  2008-08-09

4.  Adult onset reducing body myopathy.

Authors:  D Figarella-Branger; G A Putzu; C Bouvier-Labit; J Pouget; D Chateau; M Fardeau; J F Pellissier
Journal:  Neuromuscul Disord       Date:  1999-12       Impact factor: 4.296

5.  Characterization of tissue-specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM-only protein (FHL1).

Authors:  E K Ng; S M Lee; H Y Li; S M Ngai; S K Tsui; M M Waye; C Y Lee; K P Fung
Journal:  J Cell Biochem       Date:  2001 Apr 2-27       Impact factor: 4.429

Review 6.  Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features.

Authors:  Belinda S Cowling; Denny L Cottle; Brendan R Wilding; Colleen E D'Arcy; Christina A Mitchell; Meagan J McGrath
Journal:  Neuromuscul Disord       Date:  2011-04       Impact factor: 4.296

7.  Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.

Authors:  Felix W Friedrich; Brendan R Wilding; Silke Reischmann; Claudia Crocini; Patrick Lang; Philippe Charron; Oliver J Müller; Meagan J McGrath; Ingra Vollert; Arne Hansen; Wolfgang A Linke; Christian Hengstenberg; Gisèle Bonne; Stellan Morner; Thomas Wichter; Hugo Madeira; Eloisa Arbustini; Thomas Eschenhagen; Christina A Mitchell; Richard Isnard; Lucie Carrier
Journal:  Hum Mol Genet       Date:  2012-04-20       Impact factor: 6.150

8.  Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy.

Authors:  Duygu Selcen; Mark B Bromberg; Steven S Chin; Andrew G Engel
Journal:  Neurology       Date:  2011-11-16       Impact factor: 9.910

9.  Proteomic characterization of aggregate components in an intrafamilial variable FHL1-associated myopathy.

Authors:  Sarah Feldkirchner; Maggie C Walter; Stefan Müller; Christiana Kubny; Sabine Krause; Wolfram Kress; Franz-Georg Hanisch; Benedikt Schoser; Joachim Schessl
Journal:  Neuromuscul Disord       Date:  2013-03-13       Impact factor: 4.296

10.  An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1.

Authors:  Christian Windpassinger; Benedikt Schoser; Volker Straub; Sonja Hochmeister; Abdul Noor; Birgit Lohberger; Natalie Farra; Erwin Petek; Thomas Schwarzbraun; Lisa Ofner; Wolfgang N Löscher; Klaus Wagner; Hanns Lochmüller; John B Vincent; Stefan Quasthoff
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

View more
  13 in total

1.  Late-onset polyglucosan body myopathy in five patients with a homozygous mutation in GYG1.

Authors:  H Orhan Akman; Yavuz Aykit; Ozge Ceren Amuk; Edoardo Malfatti; Norma B Romero; Maria Antonietta Maioli; Rachele Piras; Salvatore DiMauro; Gianni Marrosu
Journal:  Neuromuscul Disord       Date:  2015-11-10       Impact factor: 4.296

2.  199th ENMC international workshop: FHL1 related myopathies, June 7-9, 2013, Naarden, The Netherlands.

Authors:  Anne T Bertrand; Carsten G Bönnemann; Gisèle Bonne
Journal:  Neuromuscul Disord       Date:  2014-02-14       Impact factor: 4.296

3.  Fhl1 W122S causes loss of protein function and late-onset mild myopathy.

Authors:  Valentina Emmanuele; Akatsuki Kubota; Beatriz Garcia-Diaz; Caterina Garone; Hasan O Akman; Daniel Sánchez-Gutiérrez; Luis M Escudero; Shingo Kariya; Shunichi Homma; Kurenai Tanji; Catarina M Quinzii; Michio Hirano
Journal:  Hum Mol Genet       Date:  2014-09-30       Impact factor: 6.150

4.  FHL1-related clinical, muscle MRI and genetic features in six Chinese patients with reducing body myopathy.

Authors:  ZhenXian Hu; Ying Zhu; Xiao Liu; Wei Zhang; Jing Liu; Shiwen Wu; Jiangxi Xiao; Yun Yuan; Zhaoxia Wang
Journal:  J Hum Genet       Date:  2019-07-04       Impact factor: 3.172

5.  A new titinopathy: Childhood-juvenile onset Emery-Dreifuss-like phenotype without cardiomyopathy.

Authors:  Rafael De Cid; Rabah Ben Yaou; Carinne Roudaut; Karine Charton; Sylvain Baulande; France Leturcq; Norma Beatriz Romero; Edoardo Malfatti; Maud Beuvin; Anna Vihola; Audrey Criqui; Isabelle Nelson; Juliette Nectoux; Laurène Ben Aim; Christophe Caloustian; Robert Olaso; Bjarne Udd; Gisèle Bonne; Bruno Eymard; Isabelle Richard
Journal:  Neurology       Date:  2015-11-18       Impact factor: 9.910

6.  Cardiomyopathy and altered integrin-actin signaling in Fhl1 mutant female mice.

Authors:  Akatsuki Kubota; Martí Juanola-Falgarona; Valentina Emmanuele; Maria Jose Sanchez-Quintero; Shingo Kariya; Fusako Sera; Shunichi Homma; Kurenai Tanji; Catarina M Quinzii; Michio Hirano
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 5.121

Review 7.  The sarcomeric M-region: a molecular command center for diverse cellular processes.

Authors:  Li-Yen R Hu; Maegen A Ackermann; Aikaterini Kontrogianni-Konstantopoulos
Journal:  Biomed Res Int       Date:  2015-04-15       Impact factor: 3.411

8.  A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss.

Authors:  Emilia Servián-Morilla; Hideyuki Takeuchi; Tom V Lee; Jordi Clarimon; Fabiola Mavillard; Estela Area-Gómez; Eloy Rivas; Jose L Nieto-González; Maria C Rivero; Macarena Cabrera-Serrano; Leonardo Gómez-Sánchez; Jose A Martínez-López; Beatriz Estrada; Celedonio Márquez; Yolanda Morgado; Xavier Suárez-Calvet; Guillermo Pita; Anne Bigot; Eduard Gallardo; Rafael Fernández-Chacón; Michio Hirano; Robert S Haltiwanger; Hamed Jafar-Nejad; Carmen Paradas
Journal:  EMBO Mol Med       Date:  2016-11-02       Impact factor: 12.137

9.  Mutant desmin substantially perturbs mitochondrial morphology, function and maintenance in skeletal muscle tissue.

Authors:  Lilli Winter; Ilka Wittig; Viktoriya Peeva; Britta Eggers; Juliana Heidler; Frederic Chevessier; Rudolf A Kley; Katalin Barkovits; Valentina Strecker; Carolin Berwanger; Harald Herrmann; Katrin Marcus; Cornelia Kornblum; Wolfram S Kunz; Rolf Schröder; Christoph S Clemen
Journal:  Acta Neuropathol       Date:  2016-07-08       Impact factor: 17.088

10.  Identification of a Novel Four and a Half LIM Domain 1 Mutation in a Chinese Male Presented with Hypertrophic Cardiomyopathy and Mild Skeletal Muscle Hypertrophy.

Authors:  Bing-Qing Zhang; Nuo Si; Dong-Fang Liu
Journal:  Chin Med J (Engl)       Date:  2015-08-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.